Hint mode is switched on Switch off
For swift navigation between sections

Glorincor Pharmaceuticals
TIN 7705899855, PSRN 1097746627395

Organization name
Glorincor Pharmaceuticals LLC
Country name
Russia
Country of registration
Russia
Industry
Wholesale Trade
Public debt
0.06 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

The Glorinkor company was founded in 2009 in Moscow as a consulting center to support foreign companies interested in investing in the Russian economy and developing business in the post-Soviet space. In 2015, GLORINCOR LLC was established in the Republic of Belarus to accompany foreign investors in various industries. As a result, the choice was made to accompany high-tech companies from the healthcare industry. In 2017, agreements were signed with leading Asian biopharmaceutical companies on the registration and localization of biological and generic medicines in the field of treatment of oncological, endocrinological and autoimmune diseases. The list of medicines and health products is expanding and includes medicines of various pharmacotherapeutic groups, including drugs for the treatment of cardiovascular, infectious and neurological diseases. In 2022, Glorincor signed agreements on the registration and localization of vaccines for the immunization of children against diphtheria, tetanus, pertussis, hepatitis B, hemophilic infection type b.

Awards

Documentation

Stocks

Latest issues

Bond classification

  • Organization does not disclose IFRS/US GAAP financial statements

Licenses

Public debt by currencies

Codes

  • TIN
    7705899855
  • NACE
    *** ***
  • NAICS
    *** ***
  • IEC
    770301001
  • PSRN
    1097746627395 on 15/10/2009
  • OKPO
    63684614

Issuer's quarterly reports/RAS Reports

2025
2024
2023
2022
2021
2020
2019
Show all Hide
Authorization required
You need to request access
Registration is required to get access.